Treatment with RYBREVANT ® (amivantamab-vmjw) Plus Chemotherapy Resulted in Statistically Significant and Clinically Meaningful Improvement in Progression- Free Survival in Patients with Newly Diagnosed EGFR Exon 20 Insertion Mutation- Positive Non-Small